Literature DB >> 15242952

Evolution of vaccinia virus-specific CD8+ cytotoxic T-lymphocyte responses in primary vaccinees and revaccinees.

Allan R Tenorio1, Mark E Peeples, Manokiran Patri, Katayoun Rezai, Gordon M Trenholme.   

Abstract

Determination of successful vaccination with vaccinia virus is based on visual confirmation of a dermal response (take). Some revaccinees do not manifest a take, which may be due to a preexisting immunity rather than to poor technique or inadequate virus. Cytotoxic T-lymphocyte (CTL) response appears to be the most important immune defense in limiting response to vaccination. We evaluated vaccinia virus-specific CTL responses in revaccinees. Subjects with and without takes displayed comparable CTL responses. Vaccinia virus-specific CD8+ CTL responses may be useful in interpreting the response to vaccination, particularly in individuals who are revaccinated and have difficult-to-interpret visual takes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15242952      PMCID: PMC440613          DOI: 10.1128/CDLI.11.4.758-761.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  8 in total

1.  Clinical responses to undiluted and diluted smallpox vaccine.

Authors:  Sharon E Frey; Robert B Couch; Carol O Tacket; John J Treanor; Mark Wolff; Frances K Newman; Robert L Atmar; Robert Edelman; Carrie M Nolan; Robert B Belshe
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

2.  Identification of second-site mutations that enhance release and spread of vaccinia virus.

Authors:  Ehud Katz; Elizabeth Wolffe; Bernard Moss
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Duration of antiviral immunity after smallpox vaccination.

Authors:  Erika Hammarlund; Matthew W Lewis; Scott G Hansen; Lisa I Strelow; Jay A Nelson; Gary J Sexton; Jon M Hanifin; Mark K Slifka
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

4.  PROGRESSIVE VACCINIA WITH NORMAL ANTIBODIES. A CASE POSSIBLY DUE TO DEFICIENT CELLULAR IMMUNITY.

Authors:  C J O'CONNELL; D T KARZON; A L BARRON; M E PLAUT; V M ALI
Journal:  Ann Intern Med       Date:  1964-02       Impact factor: 25.391

5.  A prospective study of serum antibody and protection against smallpox.

Authors:  T M Mack; J Noble; D B Thomas
Journal:  Am J Trop Med Hyg       Date:  1972-03       Impact factor: 2.345

6.  Dose-related effects of smallpox vaccine.

Authors:  Sharon E Frey; Frances K Newman; John Cruz; W Brian Shelton; Janice M Tennant; Tamara Polach; Alan L Rothman; Jeffrey S Kennedy; Mark Wolff; Robert B Belshe; Francis A Ennis
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

7.  Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001.

Authors:  L D Rotz; D A Dotson; I K Damon; J A Becher
Journal:  MMWR Recomm Rep       Date:  2001-06-22

8.  Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination.

Authors:  Francis A Ennis; John Cruz; Walter E Demkowicz; Alan L Rothman; David J McClain
Journal:  J Infect Dis       Date:  2002-05-17       Impact factor: 5.226

  8 in total
  1 in total

1.  Cell-mediated immune responses to smallpox vaccination.

Authors:  Sung-Han Kim; Sang-Gu Yeo; Jae-Hyun Cho; Hong-Bin Kim; Nam-Joong Kim; Myoung-don Oh; Kang-Won Choe; Youngmee Jee; Haewol Cho
Journal:  Clin Vaccine Immunol       Date:  2006-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.